Eli Lilly and Co.

Eli Lilly's Cialis faces faster-acting competition

April 30, 2012
 IBJ Staff and Bloomberg News
A Vivus Inc. pill that is supposed to provide erections within 15 minutes, about half the time or less than Eli Lilly and Co.'s Cialis or Pfizer Inc.’s Viagra,  has received U.S. regulatory approval.
More

Lilly tops analyst expectations despite shrinking profit, revenue

April 25, 2012
J.K. Wall
Lilly's quarterly sales and profit fell due to lost patent protection on Gemzar and Zyprexa. But sales of antidepressant Cymbalta, blood thinner Effient, animal health products and sales in China grew by 20 percent or more.
More

Poison pills remain as Lilly shareholder vote falls short

April 16, 2012
J.K. Wall
The proposal garnered support from the owners of 62 percent of Eli Lilly's outstanding shares. To pass, the proposal needed approval from the owners of 80 percent of Lilly’s shares.
More

Lilly CEO says cost-cutting won’t solve sales losses

April 13, 2012
Bloomberg News
Eli Lilly and Co., facing generic competition to two of its top drugs, needs to rely on new medicines rather than cost-cutting to overcome the revenue loss, CEO John Lechleiter said Thursday in Boston at the annual meeting of the Pharmaceutical Research and Manufacturers of America.
More

New Lilly drug has small sales potential

April 9, 2012
J.K. Wall
Eli Lilly and Co.’s newest drug is a boon for Alzheimer’s research but is likely to bring the Indianapolis drugmaker less than $100 million in annual sales—at least initially, according to one of the few analysts to make a forecast.
More

Lilly wins FDA approval for Alzheimer's imaging agent

April 9, 2012
J.K. Wall
The agent, called Amyvid, is not expected to produce high-dollar sales for Lilly, but it could help to identify patients with Alzheimer’s—and those without it—earlier, perhaps improving treatment and focusing research efforts.
More

Lilly receives Europe's OK for new Byetta use

March 23, 2012
 IBJ Staff and Associated Press, Associated Press
European regulators have approved an expanded use for the diabetes treatment Byetta, developed by Eli Lilly and Co. and Amylin Pharmaceuticals Inc. The FDA approved the same expanded use last fall.
More

Lilly to focus on cancer, diabetes in China, CEO says

March 20, 2012
Bloomberg News
Indianapolis-based Eli Lilly and Co. will introduce “over a dozen” new products in China in the next five years, focusing on “unmet needs” such as cancer and diabetes, CEO John Lechleiter said this week.
More

PROXY CORNER: Eli Lilly and Co.Restricted Content

March 17, 2012
Indianapolis-based Eli Lilly and Co discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
More

Lilly to try again to remove poison-pill provisions

March 6, 2012
J.K. Wall
Eli Lilly and Co.'s board is once again recommending the removal of a provision that makes the company an almost impossible target for hostile takeovers. The same proposal has fallen slightly short at each of the past two annual shareholder meetings.
More

New drugmaker code deprives docs of football, lunch for 2

March 1, 2012
Bloomberg News
Doctors can still get free samples of medicines, but not football tickets or lunch for their spouses, under a revised code of conduct drafted by a global drug industry trade group that counts Eli Lilly as a member.
More

Lilly plans 200 jobs at new $440M Ireland plant

February 27, 2012
 IBJ Staff and Bloomberg News
Eli Lilly and Co. plans to invest about $440 million in a new pharmaceutical plant at an existing company site in County Cork in southern Ireland. The facility in Kinsale will require as many as 200 skilled employees when fully operational.
More

Drugmakers singing same song: 2012 will be tough

February 2, 2012
Associated Press
For drugmakers, the golden era of the 1990s and early part of the last decade, when they seemed to effortlessly churn out new multibillion-dollar pills for the masses along with double-digit quarterly profit increases, is not even in the rearview mirror any more.
More

Lilly eying deal with Turkish drug company

January 31, 2012
Bloomberg News
Eli Lilly and Co. is among about a half-dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in a deal that may value the Turkish drugmaker at $1 billion, sources say.
More

Lilly's quarterly profit tumbles, but tops Wall Street estimates

January 31, 2012
J.K. Wall
Patent expirations on Gemzar and Zyprexa contributed to the 27-percent earnings decline, but CEO John Lechleiter touted better-than-expected sales of other products.
More

Lilly's ex-partner wins FDA approval for diabetes drug

January 29, 2012
Bloomberg News
Amylin Pharmaceuticals Inc. and Alkermes Plc have gained U.S. clearance for Bydureon, a once-weekly diabetes shot. Eli Lilly and Co. co-developed the drug, but ended its partnership with Amylin last year.
More

Eli Lilly unit plans to buy feed-enzyme maker

January 24, 2012
Associated Press
Drugmaker Eli Lilly and Co.'s Elanco animal health division plans to buy a privately held maker of feed-enzyme products that improve poultry, egg and meat production.
More

Lechleiter bets history will repeat for Lilly

January 16, 2012
J.K. Wall
Eli Lilly and Co. CEO John Lechleiter keeps pouring more money into research and development, even as analysts note the payoff of such spending has dropped off 70 percent in the last decade.
More

Lilly's Zyprexa pact with health providers wins approval

January 12, 2012
Bloomberg News
Eli Lilly and Co. has won approval of a $4.5 million settlement with five union health funds and an insurer that alleged improper marketing of the company's best-selling medication, Zyprexa, raised their costs.
More

Pressure rises as Lilly tries squeeze play

January 9, 2012
J.K. Wall
Indianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire, even as the company needs to spend more money on marketing and research to boost sales of new drugs.
More

Boston lawsuit claims DES-breast cancer link

January 8, 2012
Associated Press
Fifty-three women from around the country are suing drug companies, including Eli Lilly and Co., who made and promoted DES for millions of pregnant women from about 1938 to the early 1970s.
More

Lilly's 2012 earnings forecast misses analyst estimates

January 5, 2012
Bloomberg News, Associated Press
Indianapolis-based Eli Lilly and Co. provided a 2012 earnings forecast Thursday morning that missed analyst estimates by a wide margin, sending shares down.
More

Lilly challenging Biogen patent in London lawsuit

January 5, 2012
Bloomberg News
Eli Lilly and Co. has sued Biogen Idec Inc. in a London court to revoke a European patent on a potential treatment for immune-system diseases.
More

Lilly losing dominance in diabetes treatmentRestricted Content

December 31, 2011
J.K. Wall
Eli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses on other products that have begun to sap the drugmaker's sales.
More

Patent expirations up pressure on Lilly

December 24, 2011
Eli Lilly and Co. lost patent protection on its $5-billion-a-year best-seller Zyprexa in October, plunging the company into the long-awaited zone of uncertainty that it calls “Years YZ.”
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. From the story: "The city of Indianapolis also will consider tax incentives and funding for infrastructure required for the project, according to IEDC." Why would the City need to consider additional tax incentives when Lowe's has already bought the land and reached an agreement with IEDC to bring the jobs? What that tells me is that the City has already pledged the incentives, unofficially, and they just haven't had time to push it through the MDC yet. Either way, subsidizing $10/hour jobs is going to do nothing toward furthering the Mayor's stated goal of attracting middle and upper-middle class residents to Marion County.

  2. Ron Spencer and the entire staff of Theater on the Square embraced IndyFringe when it came to Mass Ave in 2005. TOTS was not only a venue but Ron and his friends created, presented and appeared in shows which embraced the 'spirit of the fringe'. He's weathered all the storms and kept smiling ... bon voyage and thank you.

  3. Not sure how many sushi restaurants are enough, but there are three that I know of in various parts of downtown proper and all are pretty good.

  4. First off, it's "moron," not "moran." 2nd, YOU don't get to vote on someone else's rights and freedoms that are guaranteed by the US Constitution. That's why this is not a state's rights issue...putting something like this to vote by, well, people like you who are quite clearly intellectually challenged isn't necessary since the 14th amendment has already decided the issue. Which is why Indiana's effort is a wasted one and a waste of money...and will be overturned just like this has in every other state.

  5. Rick, how does granting theright to marry to people choosing to marry same-sex partners harm the lives of those who choose not to? I cannot for the life of me see any harm to people who choose not to marry someone of the same sex. We understand your choice to take the parts of the bible literally in your life. That is fine but why force your religious beliefs on others? I'm hoping the judges do the right thing and declare the ban unconstitutional so all citizens of Wisconsin and Indiana have the same marriage rights and that those who chose someone of the same sex do not have less rights than others.

ADVERTISEMENT